

Taiwan's TWi to independently hit the US market

26 February 2015 | News | By BioSpectrum Bureau

Taiwan's TWi to independently hit the US market



Singapore: Taiwan-based TWi Pharmaceuticals has decided to sell its products in the US market through its own US subsidiary, instead of the original plan of selling through Teva Pharmaceuticals.

TWi and Teva Pharmaceuticals have reached an agreement that will transfer the United States sales and distribution rights of TWi's generic versions of Megace ES (megestrol acetate oral suspension, 625 mg/ 5 ml) and Lidoderm (lidocaine patch, 5%) from Teva to TWi. TWi will distribute both products through its wholly-owned subsidiary, TWi Pharmaceuticals USA.

TWi has assembled a sales and distribution team in the US and plans to launch several products under its label this year.

"We are excited that we are going to sell our products under the TWi label and TWi will be able to enjoy all the profits derived from the products. We are optimistic about the change, which is consistent with the company strategy," said Dr Calvin Chen, President, TWi Pharmaceuticals.